Duchenne and Becker Muscular Dystrophy

Duchenne and Becker Muscular Dystrophy Duchenne and Becker muscular dystrophy are two closely related genetic disorders characterized by progressive muscle weakness and degeneration. Both conditions stem from mutations in the DMD gene, which encodes dystrophin, a crucial protein that helps maintain the structural integrity of muscle fibers. Without functional dystrophin, muscles become fragile and more susceptible to damage over time.

Duchenne muscular dystrophy (DMD) is the more severe of the two, typically affecting boys and manifesting in early childhood. Symptoms often begin around ages 2 to 5, with children experiencing difficulty walking, frequent falls, enlarged calf muscles, and delays in motor skills development. As the disease progresses, individuals may lose the ability to walk by their early teens. Respiratory and cardiac muscles are also affected, leading to life-threatening complications. The rapid progression of DMD is primarily due to the complete or near-complete absence of dystrophin, which leaves muscle fibers vulnerable to damage and degeneration.

In contrast, Becker muscular dystrophy (BMD) is generally milder and has a later onset, often in adolescence or early adulthood. The underlying mutation in BMD typically results in a partially functional dystrophin protein. As a result, symptoms progress more slowly, and individuals may maintain ambulation for many years longer than those with DMD. Common early signs include muscle weakness in the hips and shoulders, cramps, and difficulty with physical activities. While BMD also affects cardiac muscles, the progression tends to be less aggressive, and many patients live into their 50s or beyond.

Diagnosing these conditions involves a combination of clinical evaluation, family history, blood tests measuring creatine kinase (CK) levels, genetic testing to identify DMD gene mutations, and muscle biopsies to assess dystrophin presence and quality. Early diagnosis is vital for managing symptoms, planning care, and providing genetic counseling to families, as both disorders are inhe

The image shows a woman in a medical setting. She is seated and appears to be undergoing a CT scan as indicated by the surrounding equipment.

rited in an X-linked recessive manner. This means that mostly males are affected, while females are typically carriers who may experience mild symptoms or remain asymptomatic.

Though there is currently no cure for Duchenne or Becker muscular dystrophy, advances in medical care have improved quality of life and longevity. Corticosteroids are commonly used to slow muscle deterioration, while physical therapy helps maintain mobility. Assistive devices such as braces, wheelchairs, and respiratory support are often necessary as the disease advances. Emerging therapies, including gene therapy, exon skipping, and personalized medicine, hold promise for future treatment options aiming to restore dystrophin production or mitigate muscle damage.

In summary, Duchenne and Becker muscular dystrophies are genetic disorders caused by dystrophin deficiency, with DMD being more severe and onset earlier than BMD. Understanding their differences, symptoms, and management options is vital for affected individuals and their families. Ongoing research continues to explore innovative therapies that may significantly alter the disease course and improve patients’ quality of life.

*The information on our website is not intended to direct people to diagnosis and treatment. Do not carry out all your diagnosis and treatment procedures without consulting your doctor. The contents do not contain information about the therapeutic health services of Acıbadem Health Group.